PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12728514

Interdisciplinary collaboration: the obvious need and basic structures.

Sarah Riegelhaupt·Uriel Halbreich
View original source ↗Export metadata ↓

Abstract

In the last decade there has been an exponential increase in knowledge in the field of medicine in general and particularly in Neurosciences. In order for the continuation of progress, it is important for professionals in all fields to collaborate with each other. Interdisciplinary collaboration is an absolute must to be able to obtain new knowledge, quickly and efficiently. Another important aspect is for professionals to collaborate with industry--especially the pharmaceutical industry. The global pharmaceutical companies account for a large amount of resources including personnel, knowledge, and especially funds. Although interdisciplinary collaboration is essential, many times potential partners overlook the obvious need for their own personal ongoing politics. Such competition needs to be overcome and new fields with multiple perspectives from different specialties will lead the way through the new millennium.

Explore related subjects

Drug DesignDrug IndustryHumansInterdisciplinary CommunicationMedicineNeurosciencesLecture

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sarah Riegelhaupt, Uriel Halbreich. 2003. Interdisciplinary collaboration: the obvious need and basic structures.. https://pubmed.ncbi.nlm.nih.gov/12728514/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors.

G-protein-coupled receptors (GPCRs) are the most successful target proteins for drug discovery research to date. More than 150 orphan GPCRs of potential therapeutic interest have been identified for which no activating ligands or biological functions are known. One of the greatest challenges in the pharmaceutical industry is to link these orphan GPCRs with human diseases. Highly automated parallel approaches that integrate ultra-high throughput and focused screening can be used to identify small molecule modulators of orphan GPCRs. These small molecules can then be employed as pharmacological tools to explore the function of orphan receptors in models of human disease. In this review, we describe methods that utilize powerful ultra-high-throughput screening technologies to identify surrogate ligands of orphan GPCRs.

Drug Design↗
PubMed2003

Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2).

The solution structure of a potent melanocortin receptor agonist, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2) (1) was calculated using distance restraints determined from 1H NMR spectroscopy. Eight of the lowest energy conformations from this study were used to identify non-peptide cores that mimic the spatial arrangement of the critical tripeptide region, DPhe-Arg-Trp, found in 1. From these studies, compound 2a, containing the cis-cyclohexyl core, was identified as a functional agonist of the melanocortin-4 receptor (MC4R) with an IC(50) and EC(50) below 10 nM. Compound 2a also showed 36- and 7-fold selectivity over MC3R and MC1R, respectively, in the binding assays. Subtle changes in cyclohexane stereochemistry and removal of functional groups led to analogues with lower affinity for the MC receptors.

Drug Design↗